Mutsa Madondo

RMIT University — Australia

Medicine · Health Sciences

10h-index1.7kcitations18works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(8), Immune Cell Function and Interaction(8), Reproductive System and Pregnancy(4), T-cell and B-cell Immunology(3), Cancer Immunotherapy and Biomarkers(3)

Publications18 total

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
Nature Communications·2025· 1 citedOpen Access
PP.02 Tyrosine Kinase Inhibitor (TKI) Real-World Use in Epidermal Growth Factor Receptor Mutated (EGFRm) Advanced Non-small Cell Lung Cancer (NSCLC) Patients
Journal of Thoracic Oncology·2023
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses
Cancers·2023· 10 citedOpen Access
Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer
Scientific Reports·2020· 49 citedOpen Access
Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
Cancers·2018· 13 citedOpen Access
Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells
Frontiers in Immunology·2017· 72 citedOpen Access
A flowcytometric analysis to efficiently quantify multiple innate immune cells and <scp>T</scp> Cell subsets in human blood
Cytometry Part A·2017· 25 citedOpen Access
Immunomodulatory effects of cyclophosphamide: optimising treatment for improved efficacy in patients with refractory gynaecological cancers
Figshare·2017Open Access
Immunomodulatory effects of cyclophosphamide: optimising treatment for improved efficacy in patients with refractory gynaecological cancers
Monash University·2017Open Access
Immunomodulatory effects of cyclophosphamide: optimising treatment for improved efficacy in patients with refractory gynaecological cancers
Monash University·2017Open Access
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects
Immunity·2016· 818 citedOpen Access
Low dose cyclophosphamide: Mechanisms of T cell modulation
Cancer Treatment Reviews·2015· 177 cited
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
BioMed Research International·2015· 355 citedOpen Access
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations
Journal of Translational Medicine·2014· 13 citedOpen Access
Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
American Journal of Hematology·2014· 46 cited
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment
Clinical Immunology·2013· 120 citedOpen Access
Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy (53.22)
The Journal of Immunology·2012
Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy
Immunology and Cell Biology·2012· 6 cited

Frequent Co-authors

Magdalena Plebanski(12), Michael Quinn(8), Nirmala Chandralega Kampan(4), Orla McNally(4), Chindu Govindaraj(2), Julene Hallo(2), Katie L. Flanagan(2), Andrew N. Stephens(2), John Reynolds(2), Andrew N. Stephens(2), Apriliana E. R. Kartikasari(2), Cyril Deceneux(2), Haydn Kissick(2), Demelza J. Ireland(2), Shruti Krishnan(2), Manfred W. Beilharz(2), Romain Daillère(1), Marie Vétizou(1), Nadine Waldschmitt(1), Takahiro Yamazaki(1)